Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAINT LAURENT, Quebec, June 18, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx,” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has assigned a Prescription Drug User Fee Act (“PDUFA”) action date of February 3, 2014 for the review of the Company’s New Drug Application (“NDA”) for the marketing approval of IntelGenx’ Anti-Migraine VersaFilm™ oral film product.
Help employers find you! Check out all the jobs and post your resume.
